05 / 04 / 2022
In the era of immuno-oncology, it’s critical to unravel mechanisms of action underlying sensitivity or resistance to current immunotherapies in order to identify predictive biomarkers of response and then discover novel actionable therapeutic targets.
04 / 21 / 2022
Back from the AACR 2022, it was a pleasure to take part in it and to converse about our posters showcasing our newest preclinical and translational research advances in Immuno-Oncology.
If you didn't get the chance to meet us and see our posters, or if you want to review them, you can directly download them from the form below.
03 / 29 / 2022
We will be attending the AACR Annual Meeting in New Orleans, from April 8 to 13, 2022. We will be glad to take this opportunity to meet you there, approach your research projects and introduce our service offerings. We will also presentsome scientific posters to highlight our latest innovative preclinical and translational research advances.
03 / 24 / 2022
Drawing on our expertise in multiplexed-immunohistofluoresence (IHF) and immunohistochemistry (IHC) assays, we have already developed and validated a series of markers & panels to assess several markers of interest as well as the abundance and spatial distribution of lymphoid and myeloid immune cell subsets. While bringing key answers to address specific questions, our capacities have recently been highlighted in new scientific publications of collaborative works with Institut Bergonié, which we are delighted to share thereafter.
03 / 10 / 2022
Strasbourg and Bordeaux, France, March 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), and Explicyte, an expert in the field of IO and innovative target identification through multiparametric approaches, announce today the signing of a partnership agreement. The two companies will combine their expertise to identify GPCR targets and associated biomarkers to discover and develop breakthrough therapeutic programs for IO. Financial terms are not disclosed.
02 / 22 / 2022
Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies
Journal for ImmunoTherapy of Cancer, 2022, Feb 2202 / 02 / 2022
While one of the promising cancer immunotherapy challenges is the potentiation of immune cell-induced tumor cell attacks, in vitro immune cell-mediated killing is recognized among the most relevant functional measures to evaluate the ability of candidate drugs to promote the functions of effector immune cells. We set up and designed specialized in vitro immune cell killing assays - either T cell- or NK-mediated - to test candidate compounds or antibodies for their immunomodulatory properties in enhancing the immune response against tumor cells.
01 / 31 / 2022
Frontiers Immunology, 2022, Jan 31
F. Peyraud, JP. Guegan, D. Bodet, S. Cousin, A. Bessede, A. Italiano
01 / 27 / 2022
January 27, 2022 – The CONDOR consortium, led by Pr. Antoine Italiano of the Bergonié Institute (Bordeaux, France) is one of the 17 national awardees in the fifth call for projects in Hospital-University Research in Health (RHU5), selected from the 89 applications submitted. This €30M ($34M) project will benefit from a grant of more than €9.8M ($11.1M) to implement a multi-modal project combining precision medicine and immunotherapies for the management of patients with Soft Tissue Sarcomas (STS).
01 / 13 / 2022
To pursue our commitment to expand cutting-edge approaches for the identification and discovery of novel biomarkers and actionnable therapeutic targets, we implemented the GeoMx DSP technology platform which was already referenced in scientific publications this year, notably in JITC and Nature Medicine.